...Introduction The world is a cold place these days for businesses seeking profitable international growth. In a few industries, firms have to be global if they are to achieve leadership. Implementing a global expansion strategy is crucial to the growth of a business from small start-up to international brand name. Companies such as McDonald's, Home Depot, Starbucks and more have made their presence known around the world over the past few decades. However, each global expansion presents its own set of obstacles which the parent company must tackle, in order to be successful in their global expansion. In a borderless world, companies need to compete on a global level in order to succeed. In today's world of financial uncertainty, it is important for businesses to have a clear idea of what stability involves for their company. One concept that more and more businesses are exploring is one of taking their business to a global level. Using an international strategy is not for every company, but with the availability of the Internet it is becoming easier to take your business to that next level. Global expansion may enable a firm to earn greater returns by transferring the product offerings derived from its core competencies to markets where indigenous competitors lack those product offerings and competencies. One of the global expansion strategies is merger and acquisition. Five waves of mergers and acquisitions took place in the 20th century, with the last two occurring...
Words: 4340 - Pages: 18
...Global Pharma Industry ............................................................................................................................ 3 Major players of the world pharmaceutical industry ................................................................................... 5 Major Players ............................................................................................................................................ 6 Pfizer Inc................................................................................................................................................ 6 GlaxoSmithKline .................................................................................................................................... 6 Sanofi-Aventis ....................................................................................................................................... 6 Novartis ................................................................................................................................................. 6 Indian Pharma Industry................................................................................................................................. 7 Drivers of the Demand .............................................................................................................................. 7 Drivers of Supply...
Words: 7934 - Pages: 32
...Pharmaceutical Sector of Bangladesh The pharmaceutical industry in Bangladesh is one of the most developed technology sectors within Bangladesh. Manufacturers produce insulin, hormones, and cancer drugs. This sector provides 97% of the total medicinal requirement of the local market. The industry also exports medicines to global markets, including Europe. Pharmaceutical companies are expanding their business with the aim to expand the export market. History Right after liberation war three fourth of the pharmaceutical industries was dominated by multinational companies. The National Drug Policy (NDP) in 1982 and 2005 has major impact in the development and growth of the Bangladesh pharmaceutical industry. Key points of National Drug Policy of 1982 To provide administrative and legislative support for ensuring quality of essential drugs which are relevant to the national health need. To reduce the price of medicine by ensuring the lowest competitive price. To eliminate non-essential medicine from the market To promote production of local drug and raw materials. To develop proper drug monitoring and information system to prevent wasteful misuse and to ensure the proper utilization of the drugs. To ensure GMP and qualified pharmacist in manufacturing companies. Drug Regulatory Authorities in Bangladesh • The Directorate General of Drug Administration (DGDA) • The Pharmacy Council of Bangladesh (PCB) Local Market Overview The Bangladesh...
Words: 998 - Pages: 4
...LIST OF COMPANIES American Express Amway Anand Axis Castrol Deloitte Ernst & Young FINO Godrej Maruti Ingersol Rand Inno Park L&T Madura Marg Group Mercer Metro Cash and Carry Naukri Tata Sons Tata Motors TVS Motors Marico Religare Standard Chartered Sanofi UBI American Express (India) Private Ltd Vision: We work hard every day to make American Express the world’s most respected service brand Slight History – Parent company is an American multinational financial services. Founded in 1850, it is one of the 30 components of the Dow Jones Industrial Average. The company is best known for its credit card, charge card, and traveler'scheque businesses. Amex cards account for approximately 24% of the total dollar volume of credit card transactions in the US, the highest of any card issuer. American Express (India) Private Ltd. offers accounting and financial processes consolidation services to the American Express Company’s businesses. The company was founded in 1994 and is based in Gurgaon, India. American Express (India) Private Ltd. operates as a subsidiary of American Express International Inc. and American Express Limited. Basics Non-Listed, Limited Liability Company Net operating revenues increased 4.01%, (INR 812.33 to INR 844.89 tens of millions) Operating result increased 7.59% (INR 175.98 to INR 189.33 tens of millions) Net Profit Margin (Net Income/Net Sales) from 24.52% to 13.68% Employee 6158 • s Key • People Sanjay Rishi CEO India HR practices –...
Words: 14529 - Pages: 59
...INTRODUCTION Training is a learning process that involves the acquisition of knowledge, sharpening of skills, concepts, rules, or changing of attitudes and behaviors to enhance the performance of employees. There are various methods of training, which can be divided in to cognitive and behavioral methods. Trainers need to understand the pros and cons of each method, also its impact on trainees keeping their background and skills in mind before giving training. Cognitive methods are more of giving theoretical training to the trainees. They provide the rules for how to do something, written or verbal information, demonstrate relationships among concepts, etc. These are associated with changes in knowledge and attitude by stimulating learning. The various methods are: * LECTURES * DEMONSTRATIONS * DISCUSSIONS * COMPUTER BASED TRAINING (CBT) * INTELLEGENT TUTORIAL SYSTEM(ITS) * PROGRAMMED INSTRUCTION (PI) * VIRTUAL REALITY Behavioral methods are more of giving practical training to the trainees. They allow the trainee to behavior in a real fashion. These are best used for skill development. The various methods are: * GAMES AND SIMULATIONS * BEHAVIOR-MODELING * BUSINESS GAMES * CASE STUDIES * EQUIPMENT STIMULATORS * IN-BASKET TECHNIQUE * ROLE PLAYS Management development is the more future oriented method and more concerned with education of the employees. To become a better performer...
Words: 3005 - Pages: 13
...Q3 2010 www.businessmonitor.com siNGapore pharmaceuticals & healthcare report INCLUDES 10-YEAR FORECASTS TO 2019 issN 1748-216X published by Business monitor international ltd. SINGAPORE PHARMACEUTICALS & HEALTHCARE REPORT Q3 2010 INCLUDING 5-YEAR AND 10-YEAR INDUSTRY FORECASTS BY BMI Part of BMI’s Industry Report & Forecasts Series Published by: Business Monitor International Copy deadline: June 2010 Business Monitor International Mermaid House, 2 Puddle Dock, London, EC4V 3DS, UK Tel: +44 (0) 20 7248 0468 Fax: +44 (0) 20 7248 0467 Email: subs@businessmonitor.com Web: http://www.businessmonitor.com © 2010 Business Monitor International. All rights reserved. All information contained in this publication is copyrighted in the name of Business Monitor International, and as such no part of this publication may be reproduced, repackaged, redistributed, resold in whole or in any part, or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping, or by information storage or retrieval, or by any other means, without the express written consent of the publisher. DISCLAIMER All information contained in this publication has been researched and compiled from sources believed to be accurate and reliable at the time of publishing. However, in view of the natural scope for human and/or mechanical error, either at source or during production, Business Monitor International accepts no...
Words: 29653 - Pages: 119
...ESSAY 3 HEALTH IN THE TROPICS STATE OF THE TROPICS causes of mortality. Improvements in quality of life through improved health are harder to quantify accurately at scale. Life Expectancy Life expectancy is covered in detail elsewhere in the State of the Tropics, and reports that between 1950 and 2010 the gap between life expectancy in the Tropics and the Rest of the World has narrowed. Over this period life expectancy in the Tropics increased by 22.8 years to 64.4 years and infant mortality reduced by 36%. The rate of change of mortality and morbidity has increased over the last two decades influenced by a range of different factors. Underlying life expectancy data are aggregated data, collected by the WHO to document the changing patterns of mortality. Table E3.1 provides the top ten causes of mortality in rank order over the last decade. Non-communicable diseases (NCDs) accounted for two-thirds of global deaths in 2011 and infectious diseases for one-third. In 2000 the relative proportions were 60% NCDs and 40% infectious diseases. This rapid shift reflects the massive scale up in recent efforts to prevent and treat a number of major infectious diseases. Although improvements in maternal and child mortality have been made these still remain unacceptably high. In 2011, 6.9 million children under the age of five died, 99% of these in low and middle income countries. Malaria, despite the enormous scale up in control activities still ...
Words: 5155 - Pages: 21
...COUNTRY ANALYSIS REPORT: MEXICO VS U.S.A HEALTHCARE MERCK - DIABETES Group 14 – Campus Santa Fe: Angelica Hidalgo 1461526 Alejandro Meza 1464801 Cinthia Merlos 1462113 Juan José Ibarra 1465263 April 10th, 2012 INDEX 1. INTRODUCTION 2. ECONOMIC VARIABLES 3. POLITICAL VARIABLES 4. SOCIO –CULTURAL AND DEMOGRAPHIC VARIABLES 5. COUNTRY ATTRACTIVENESS SCORE 6. THE DECISION 7. EXHIBITS 8. BIBLIOGRAPHY 1. INTRODUCTION 2. ECONOMIC VARIABLES The total economic impact of diabetes worldwide In the world the economic impact about the diabetes was 376 billion dollar in 2010, this is the 11.6% of the total healthcare budget in the world. This facts give us an idea about how is important to analyze the impact in economies of this disease and we are going to go deeper for the analysis of Mexico and United States of America. MEXICO In Mexico the economic impact due to diabetes cost more than 7 billion dollars in 2011 according to the Instituto Nacional de Salud Publica. And is expected an increase of 15% this year of 2012 this impact is really huge because 50% of this expense was made by families and the other 50% was made by government in Latin America Mexico is the country...
Words: 4412 - Pages: 18
...STRATEGY 2015 Articles | Books & Chapters | Cases | Core Curriculum Course Modules | Simulations | Video Harvard Business Publishing serves the finest learning institutions worldwide with a comprehensive catalog of case studies, journal articles, books, and elearning programs, including online courses and simulations. In addition to material from Harvard Business School and Harvard Business Review, we also offer course material from these renowned institutions and publications: ABCC at Nanyang Tech University Babson College Berrett-Koehler Publishers Business Enterprise Trust Business Expert Press Business Horizons California Management Review Crimson Group USA Darden School of Business Design Management Institute European School of Management and Technology (ESMT) Haas School of Business Harvard Kennedy School of Government Harvard Medical School/Global Health Delivery HEC Montréal Centre for Case Studies IESE Business School Indian Institute of Management Bangalore Indian School of Business INSEAD International Institute for Management Development (IMD) Ivey Publishing Journal of Information Technology Kellogg School of Management McGraw-Hill MIT Sloan Management Review North American Case Research Association (NACRA) Perseus Books Princeton University Press Rotman Magazine Social Enterprise Knowledge Network Stanford...
Words: 5151 - Pages: 21
...1. Historical background Beximco Pharmaceuticals Limited (BPL) is a part of Beximco Group, the largest private sector industrial conglomerate in Bangladesh. BPL develops, manufactures and markets both finished dosage form branded generic pharmaceutical products and active pharmaceutical ingredients (APIs), with products including solid dose forms, Metered Dose Inhalers, Nasal Sprays, Large Volume Intravenous Fluids, Suppositories, and Creams/Ointments. BPL produces and markets 'branded generics' for most diseases ranging from AIDS to cancer, from infection to asthma, from hypertension to diabetes, for both national and international markets. The company also manufactures active pharmaceutical ingredients and intravenous fluids and contract manufacture for major international brands of leading multinational companies. BPL utilizes state of the art manufacturing facilities. BPL also has outstanding reverse engineering capabilities. Incorporated in 1976, BPL started off as a distributor of pharmaceutical products. It imported products from global MNCs such as Bayer AG of Germany and Upjohn Inc. of USA and sold them in the local market. It eventually graduated to a manufacturer and distributor of these products in local market under licensing agreements. During the early 80s, BPL launched its own products in the local market. Beximco started its exports operation in the early 90s with APIs. Today BPL is one of the largest exporters of medicines from Bangladesh. BPL employs more...
Words: 1988 - Pages: 8
...Issue 5 / China’s chronic disease challenge Features from our global market research experts Free Thinking China’s chronic disease challenge Marc Yates, Director of Emerging Markets, looks at the chronic disease challenge in China and asks what it means for China’s healthcare policy and to global pharmaceutical companies looking to operate in this double-digit growth market. In 2012 the urban population exceeded the rural population for the first time. Urbanisation brings significant benefits such as improved sanitation, greater affordability and increased access to healthcare. It also changes the disease paradigm with a reduction of infectious diseases but an increase in diseases of affluence, such as cardiovascular diseases and diabetes. The diabetes problem Research from Peking University suggests that China now has more diabetes patients than even India and it is hitting the country hard. In 2007 almost 600,000 adult deaths in China were directly attributable to diabetes, and there was a significant gender difference, with males accounting for 57% of all diabetes-related deaths. And the diabetes problem is not getting any easier. The International Diabetes Federation predicts the health expenditure to increase by an average of 20% between 2007 to 2025 across the Western Pacific region. However during the same period spending on diabetes in China is forecasted to grow by 49%. Health expenditure for diabetes 2007 US$ (‘000) 2025 US$ (‘000) % Increase China Western Pacific...
Words: 2328 - Pages: 10
...Abstract The aim of the study is to present the current scenario of the pharmaceutical industry in Bangladesh. In Bangladesh, the pharmaceutical sector is one of the most developed hi-tech sectors, which is contributing in the country’s economy. After promulgation of Drug Control Ordinance -1982, the development of this sector was accelerated. The professional knowledge, thoughts and innovative ideas of the pharmaceutical professionals working in this sector are the key factors for this development. Due to resent development of this sector, it is exporting medicines to global markets including highly regulated European markets. This sector also providing 97% of the total medicine requirement of the local market. Leading pharmaceutical companies are expanding their business with the aim to expand export market recently few new companies have been established with hi-tech equipments and high professionals which will enhance the strength of this sector. Government declared “Pharmaceuticals as the product of the year (2008), in a bid to boost it export further, such a move is the first in Bangladesh and pharmaceuticals has been single out considering its tremendous prospect in the global market and diversification of basket as well as Bangladesh pharmaceuticals industry is the highest among the LDCs and growing with 50% annually. Bangladesh pharmaceuticals industry is one of the first growing sector in Bangladesh among the 50 LDCs. Bangladesh is the only country that is nearly self...
Words: 2796 - Pages: 12
...High-Technology Acquisitions Final Project -Acquisition Proposal: To Acquire: May 2012 Table of Content Executive Summary I A. Purpose I B. Background I C. The Rational for the Acquisition I D. Standalone, Synergy and Premium Valuations II E. Integration Plan II Part 1 - The Rational of the Acquisition 1 1. Pfizer's Strategy 1 1.1. Pfizer Growth Strategy 2 2. Pfizer's Road Map 4 2.1. Pfizer's Acquisitions Rational 4 3. The strategy behind the acquisition 5 3.1. Acquisition Motives 5 3.2. M&A vs. Alliance 5 4. Target Identification 7 4.1. Protalix - an R&D Acquisition 9 5. Synergy Analysis 10 6. Standalone, Synergy and Premium Valuations 12 6.1. Market Value 12 6.2. Trading and Transaction Multiples Valuations 12 6.3. Discounted Cash Flow (DCF) Valuation 14 6.3.1. DCF Methodology and Assumptions 14 6.3.2. Summary of the Standalone and the Synergy DCF Valuation 15 6.4. Premium 16 6.5. Walk-away Price, Net Value Creation and Financial Feasibility 17 Part 2 - The Integration Plan 18 Bibliography 21 APPENDIXES 22 Appendix 1 - Pfizer's Executive Leadership Team 23 Appendix 2 - Pfizer's Organizational Structure Scheme 24 Appendix 3 - Five Forces Analysis for the Pharmaceutical Industry 25 Appendix 4 - Pfizer's PEST Analysis 27 Appendix 5 - Level of Competition Between the Acquirers & the Uniqueness of the Acquired Company 31 Appendix 6 - Acquisition Motives 33 Appendix 7 - Protalix...
Words: 10031 - Pages: 41
...Xalatan/Xalacom Chantix Rebif Zmax Detrol/Detrol LA Relpax Zoloft Eraxis Revatio Zyvox Animal Health Products BoviShield Draxxin RespiSure/Stellamune Cerenia Excede Revolution/Stronghold Clavamox/Synulox Improvac Rimadyl Convenia Lutalyse Silentrol Dectomax Naxcel/Excenel Financials Stock Symbol: PFE Price Range: $11-$18 Sales (2008): $48,296,000,000 Net Income: $8,104,000,000 Net Assets: $109,892,000,000 Key Executives CEO: Jeff Kindler CFO: Frank D'Amelio CMO (Chief Medical Officer): Freda C. Lewis-Hall Key Competitors GlaxoSmithKline Johnson & Johnson Novartis AG Roche Holding-AG Sanofi-Aventis Mergers and Acquisitions (2008-2009) Wyeth: announcement of merger 1/26/09, biopharmaceutical Auxilium Pharmaceuticals: 12/08, develops Xiaflex-first in class biologic for treatment of Dupuytren’s contracture and Peyronie’s Disease Schering-Plough Corportation: 4th quarter 2008, animal health products Medivation, Inc.: 9/08, develops Dimebon an investigational drug for treatment of Alzheimer’s and Huntington’s Disease Encysive: 2nd quarter 2008, biopharmaceutical company develops Thelin for the treatment of pulmonary artery hypertension Celldex: 2nd quarter 2008, develops CDX-110 an experimental...
Words: 7035 - Pages: 29
...At the Intersection of Health, Health Care and Policy Cite this article as: Henry G. Grabowski, Joseph A. DiMasi and Genia Long The Roles Of Patents And Research And Development Incentives In Biopharmaceutical Innovation Health Affairs, 34, no.2 (2015):302-310 doi: 10.1377/hlthaff.2014.1047 The online version of this article, along with updated information and services, is available at: http://content.healthaffairs.org/content/34/2/302.full.html For Reprints, Links & Permissions: http://healthaffairs.org/1340_reprints.php E-mail Alerts : http://content.healthaffairs.org/subscriptions/etoc.dtl To Subscribe: http://content.healthaffairs.org/subscriptions/online.shtml Health Affairs is published monthly by Project HOPE at 7500 Old Georgetown Road, Suite 600, Bethesda, MD 20814-6133. Copyright © 2015 by Project HOPE - The People-to-People Health Foundation. As provided by United States copyright law (Title 17, U.S. Code), no part of Health Affairs may be reproduced, displayed, or transmitted in any form or by any means, electronic or mechanical, including photocopying or by information storage or retrieval systems, without prior written permission from the Publisher. All rights reserved. Not for commercial use or unauthorized distribution Downloaded from content.healthaffairs.org by Health Affairs on February 29, 2016 at UNIV OF CALIFORNIA Intellectual Property & Innovation By Henry G. Grabowski, Joseph A. DiMasi, and Genia Long 10.1377/hlthaff...
Words: 7115 - Pages: 29
